- Home
- TEM vs PCVX Comparison
TEM vs PCVX Comparison
Compare TEM & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEM
- PCVX
- Stock Information
- Founded
- TEM 2015
- PCVX 2013
- Country
- TEM United States
- PCVX United States
- Employees
- TEM N/A
- PCVX N/A
- Industry
- TEM
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- TEM
- PCVX Health Care
- Exchange
- TEM NYSE
- PCVX Nasdaq
- Market Cap
- TEM 11.9B
- PCVX 4.4B
- IPO Year
- TEM 2024
- PCVX 2020
- Fundamental
- Price
- TEM $60.74
- PCVX $33.25
- Analyst Decision
- TEM Buy
- PCVX Strong Buy
- Analyst Count
- TEM 12
- PCVX 10
- Target Price
- TEM $65.09
- PCVX $136.50
- AVG Volume (30 Days)
- TEM 11.2M
- PCVX 1.5M
- Earning Date
- TEM 08-05-2025
- PCVX 08-05-2025
- Dividend Yield
- TEM N/A
- PCVX N/A
- EPS Growth
- TEM N/A
- PCVX N/A
- EPS
- TEM N/A
- PCVX N/A
- Revenue
- TEM $803,315,000.00
- PCVX N/A
- Revenue This Year
- TEM $81.57
- PCVX N/A
- Revenue Next Year
- TEM $24.86
- PCVX N/A
- P/E Ratio
- TEM N/A
- PCVX N/A
- Revenue Growth
- TEM 42.93
- PCVX N/A
- 52 Week Low
- TEM $30.77
- PCVX $27.66
- 52 Week High
- TEM $91.45
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- TEM N/A
- PCVX 45.61
- Support Level
- TEM N/A
- PCVX $32.00
- Resistance Level
- TEM N/A
- PCVX $34.63
- Average True Range (ATR)
- TEM 0.00
- PCVX 1.33
- MACD
- TEM 0.00
- PCVX -0.06
- Stochastic Oscillator
- TEM 0.00
- PCVX 33.67
About TEM TEMPUS AI INC
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.